Expert comments

Comments on this technology were invited from clinical experts working in the field and relevant patient organisations. The comments received are individual opinions and do not represent NICE's view.

Five experts were familiar with or had used this technology before.

Level of innovation

Four expert commentators agreed that the technology is innovative. One expert noted that people with chronic obstructive pulmonary disease (COPD) currently receive lots of written information (such as paper leaflets), and myCOPD could allow people to access all relevant information about their condition in one place. People would be able to access information and services (such as pulmonary rehabilitation) in their own homes.

Potential patient impact

The main benefits identified by the expert commentators were improvements in self-management and education, and support for pulmonary rehabilitation. The technology offers training on inhaler technique and breathing control, helping people to manage their symptoms themselves. The experts thought the technology was accessible to any people with COPD who have access to the internet and a suitable device.

Potential system impact

A key benefit to the healthcare system would be a reduction in the use of NHS resources. Four experts thought that the use of myCOPD could potentially improve people's independence, help them manage their own condition, and reduce the need for GP appointments and hospital admissions. The expert commentators also identified possible reductions in staff time spent on patient education.

Four experts thought there would be little change to current facilities or infrastructure.

The experts noted that training would be needed for both healthcare professionals and people with COPD, but they thought this would be simple and brief. For example, staff might need an hour to learn how to navigate the app, and how to set it up for people with COPD.

General comments

Three experts expected myCOPD to be used as an add-on intervention to current standard care for COPD management. One expert suggested that myCOPD has been used as a part of a COPD bundle, to be offered to people as an aid for self-management. None of the experts were aware of any safety issues reported, but 1 expert indicated the need for people to have an assessment before they are referred onto online pulmonary rehabilitation, to ensure clinical safety. Two experts identified the main barriers to adoption as a lack of robust evidence to support the benefit outside the context of trials, and the cost of the technology.

One expert noted that service providers have been using myCOPD to support people after pulmonary rehabilitation since the outbreak of COVID-19. The expert shared a patient's story using myCOPD.